A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

NCT07615426 · tracked via the Priya Life Science USA tracker

Sponsor

Janssen Research & Development, LLC

Phase

Phase 1

Started

2026-03-02

Last updated

2026-08-28

Condition(s) studied

Schizophrenia

Investigational drug(s) / intervention(s)

AticaprantPlacebo

Aticaprant: Participants will receive aticaprant during the double blind (DB) treatment phase.

Placebo: Participants will receive placebo during the DB treatment phase.

Study summary

The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

Eligibility

Sex

ALL

Min age

18 Years

Max age

55 Years

Healthy volunteers

Inclusion criteria: * Clinically stable with a diagnosis of schizophrenia confirmed by the mini international neuropsychiatric interview \[MINI\] for psychotic disorders * The participant must be on a stable dose of only one atypical antipyschotic medication * Must be receiving outpatient treatment for schizophrenia from a psychiatric provider at the time of screening * At the Baseline visit, must have a presence of permitted background antipsychotic medication based on blood samples drawn at the screening visit * If taking an antidepressant or anxiolytic, no dose changes are allowed to have occurred within 8 weeks prior to screening or throughout the double blind treatment phase Exclusion criteria: * Has one or more of the current or prior (lifetime) diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnoses (based on the MINI for psychotic disorders): intellectual disability, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder not otherwise specified (NOS), substance-induced psychotic disorder, bipolar disorder, major depressive disorder (recurrent or current episode) * Has a history of moderate-to-severe substance use disorder, including alcohol use disorder, according to DSM-5 criteria within 6 months before screening except for nicotine or caffeine (based on the MINI and clinical judgment) * Current cannabis (marijuana, pot, grass, hash, etcetera) use exceeds 3 to 5 times over the past 30 days as measured by items from the national survey on drug use and health (NSDUH) questionnaire * Has a history in the past 6 months of a peptic ulcer, or lifetime history of upper gastrointestinal bleeding, or known untreated helicobacter pylori infection, or has a diagnosis of zollinger-ellison syndrome (ZES) * Has current homicidal ideation/intent, per the investigator's clinical judgment

Primary outcome measure(s)

Screen Pass Rate — Up to 28 days
Screening pass rate of participants will be reported.
Exploratory Assessment-Specific Completion Rate — Up to 126 days
Assessment specific completion rate of participants will be reported.
Total Assessment Completion Rate — Up to 126 days
Study Completion Rate — Up to 126 days
Adverse Events (AEs) Including AEs of Special Interest (AESI) — Up to 126 days
Number of Participants with Abnormalities in Vital Signs — Up to 126 days
Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG) — Up to 84 days
Number of Participants with Abnormalities in Laboratory Parameters — Up to 84 days
Number of Participants Reporting Changes in Body Weight — Up to 84 days
Number of Participants Reporting Changes in Body Mass Index (BMI) — Up to 84 days
Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over Time — Up to 126 days
The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the occurrence and intensity of suicidal thoughts and suicidal behaviors.
Extrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total Score — Up to 84 days

Trial sites (8)

Facility	City	Region	Status
CNS Network	Garden Grove	California	Recruiting
Synexus Clinical Research US Inc	Atlanta	Georgia	Recruiting
Uptown Research Institute	Chicago	Illinois	Recruiting
Western Michigan University	Kalamazoo	Michigan	Recruiting
Neurobehavioral Research Inc	Cedarhurst	New York	Recruiting
Evolution Research Group	Staten Island	New York	Recruiting
Community Clinical Research, Inc.	Austin	Texas	Recruiting
Pillar Clinical Research, LLC	Richardson	Texas	Recruiting

More Janssen Research & Development, LLC trials in the USA

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma Active, not recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma Recruiting

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer Active, not recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Recruiting

Other trials for the same condition

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia Recruiting

Study of SPG302 in Adults With Schizophrenia Active, not recruiting

Study of ALTO-101 in Patients With Schizophrenia Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07615426 on ClinicalTrials.gov ↗ ← All trials in the USA